Navigation Links
Mylan Confirms First-to-File Patent Challenge Relating to Generess™ Fe
Date:12/1/2011

PITTSBURGH, Dec. 1, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it and Famy Care Ltd. have been sued by Warner Chilcott Company LLP, in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Norethindrone and Ethinyl Estradiol Chewable Tablets, 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets. This product is the generic version of Generess™ Fe, a 28-day regimen indicated for use by women to prevent pregnancy.

Mylan believes that this application submitted to the FDA is the first substantially complete ANDA containing a Paragraph IV certification and expects it to qualify for 180 days of marketing exclusivity upon final approval. In 2008, Mylan and Famy Care entered into a partnership to develop and supply oral contraceptives. Warner Chilcott filed the lawsuit in the U.S. District Court for the District of New Jersey.

Since launching in April 2011 and through Sept. 30, 2011, Generess Fe had sales of $4.5 million, according to IMS Health.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first-to-file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment
2. Mylan Receives Approval for Generic Version of Zinecard® for Injection
3. Mylan Announces Settlement Agreement for its First-to-File Generic Version of Vivelle-Dot®
4. Mylan Successfully Upsizes and Completes Refinancing of Credit Facility
5. Mylan Applauds Obama Administrations Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
6. Mylan to Acquire Pfizer Respiratory Delivery Platform
7. Mylan Receives Approval for Generic Version of MS Contin® Tablets
8. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
9. Mylans Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents
10. Matrix Laboratories Completes Name Change to Mylan Laboratories
11. Mylan Announces Femcon® Fe Settlement Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 23, 2016 Experts from various ... Medicine and the role of technology in innovative ... The First International Conference of VPS-Penn Medicine opened in ... and presence of Sheikh Nahyan bin Mubarak Al Nahyan, Minister ... Medicine, which helps provide personalized medicine and tailor-made healthcare in ...
(Date:5/23/2016)... , May 23, 2016 The ... USD 5.0 billion by 2022, according to a new ... of medical waste coupled with the lack of centralized ... expected to drive the demand for reprocessed medical devices ... as compared to that of the original device is ...
(Date:5/22/2016)... DUBLIN , May 23, 2016 ... to develop its anti-fibrotic and anti-inflammatory compound DS102 ... well as in non-alcoholic steatohepatitis (NASH) patients. ... is significantly sequestered in lung tissue and has ... tissue after oral administration. The Company will publish ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... 2016 , ... Global Lyme Alliance (GLA), a leading nonprofit ... has named Scott Santarella as its new CEO. , Santarella is former ... San Francisco, where he successfully helped to grow the organization from a regional ...
(Date:5/24/2016)... ... May 24, 2016 , ... Researchers ... of protocols designed to reduce bleeding complications from percutaneous coronary intervention (PCI). The ... Interventions (SCAI) in Orlando, FL, document a 40% reduction in risk-adjusted bleeding event ...
(Date:5/24/2016)... ... May 24, 2016 , ... Design Concepts ... ‘El Centro del Quinto Sol Wheel Park’ in Pueblo, Colorado. This park was ... offer something special for this often overlooked neighborhood. Located at 609 E. 6th ...
(Date:5/24/2016)... ... May 24, 2016 , ... Celebration is in ... kicked off its 5th Annual Photo Contest. The label contest is underway, and ... year's prizes include a GoPro Hero4, a 40-inch high-definition flat-screen television, an Apple ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... On the ... took the time to summarize the weight loss process: , New patients have a ... Composition Analysis (BCA) to get accurately evaluated. , Body Composition Analysis, There are 15 ...
Breaking Medicine News(10 mins):